Skip to content
Menu

Real moms, real GLP-1 talk

Zepbound vs Wegovy: Which Is Right for You?

Zepbound beat Wegovy in a head-to-head trial. But as a mom, side effects, cost, breastfeeding timing, and birth control decide it too. An honest rundown.

Walked and written by Jenna Marsh — a mom doing this herself, not a treating clinician
On this page

The short version, mom to mom

When I started digging into this, everyone in my group chat talked about Zepbound and Wegovy like they were the same shot with different labels. They're not. They're the two FDA-approved brand-name injections for weight loss, and there's finally a head-to-head trial that separates them: over 72 weeks, Zepbound produced meaningfully more weight loss than Wegovy and was declared superior on that measure1. So if you only care about the bigger number, that's your answer.

But here's what actually happened when I tried to make this decision for real life: the number stopped being the whole story. Side effects, cost, breastfeeding and pregnancy timing, and a birth-control interaction that hits Zepbound but not Wegovy all crashed the party. If you're a mom weighing these, those belong in the same conversation as the efficacy headline.

One naming thing first, because it tripped me up: Zepbound and Wegovy are the brands approved for weight loss. The exact same two molecules are sold as Mounjaro (tirzepatide) and Ozempic (semaglutide) for type 2 diabetes. Same drugs, different brand and indication. If your friend "did great on Mounjaro," that's tirzepatide — the Zepbound molecule.

Boundary I hold myself to: I don't create accounts, enter medical info, or check out — this is education from the public funnel and published research, not medical advice. I checked every clinical claim below against FDA labels and published trials.

The head-to-head data (finally a real one)

For a long time these comparisons leaned on separate trials, which is a bit like arguing whose kid is taller from two different school photos. Now there's a direct one. SURMOUNT-5 randomized 751 adults with obesity to Zepbound or Wegovy for 72 weeks at their maximum tolerated doses. Mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, and tirzepatide came out superior for both weight and waist-circumference reduction1.

That tracks with each drug's own pivotal trial — semaglutide produced about 15% average weight loss in STEP 12, and tirzepatide about 20% at the top dose in SURMOUNT-13 — so this isn't one weird study. The direction is consistent across the evidence.

The honest caveat I keep reminding myself of: "more on average" is a fact about groups, not about me. Plenty of women lose a lot on semaglutide, tolerate it better, or pay less for it. The trial tells you where the averages point, not where any single mom lands.

Side effects: same family, mostly during the dose climbs

Both are built on GLP-1 signaling (Zepbound adds a second target, GIP), so the side-effect profile rhymes. The gastrointestinal stuff — nausea, diarrhea, constipation, vomiting — is the most common with both, most of it is mild to moderate, and it clusters during the dose-escalation phase rather than at a stable maintenance dose1. Neither one is reliably the "gentle" option; tolerance is personal. A good program titrates slowly and switches you if a molecule just doesn't sit right.

If the side-effect question is the one keeping you up, I wrote a whole practical rundown in managing GLP-1 side effects — what actually helped me and when it's a call-your-clinician moment.

Staying there: the maintenance question a mom actually asks

Weight loss that snaps back the second you stop isn't the goal, and this is where the mom lens earns its keep. Both drugs are studied as ongoing treatments. When semaglutide was stopped and switched to placebo, much of the lost weight came back4. Continuing tirzepatide, on the other hand, held the reduction where stopping did not5. If you might pause treatment for a pregnancy someday, "what happens when I stop, and how do I restart?" is a far more useful question than "which number is bigger?" I dug into that in what really happens when you stop a GLP-1.

Cost and access (the part that decided it for a lot of us)

Zepbound is frequently priced higher than Wegovy, and there's a formal cost-effectiveness analysis built on the SURMOUNT-5 results that looked at that value trade-off directly in the US6. Both manufacturers run savings programs, both come as fixed-dose pens, and real-world availability of each has swung with shortages. For most moms I know, the practical driver isn't the trial — it's what insurance covers and what the actual out-of-pocket number is. Price it before you fall in love with a molecule; my cheapest-GLP-1 board and how much a GLP-1 really costs without insurance are where I'd start.

The mom-specific stuff a brand comparison skips

Two facts matter here that a straight efficacy chart leaves out completely:

  • Birth control. The Zepbound label carries an explicit warning that oral hormonal contraceptives may become less effective, and it advises switching to a non-oral method or adding a barrier method around starting the drug and around each dose increase7. The Wegovy labeling does not carry that specific warning8. If you rely on the pill, that is not a footnote — that's a real, practical difference between the two.
  • Breastfeeding and pregnancy timing. Both are off the table during pregnancy and while nursing, and both linger roughly a week per dose, so the washout math is broadly similar. If you're breastfeeding or planning to conceive, the timing plan matters more than the molecule — our guide to GLP-1s while breastfeeding walks through how clinicians think about it.

How I'd actually choose

The averages favor Zepbound, but averages aren't people. Tolerance, cost, what your insurance covers, whether you take the pill, and your pregnancy plans all feed a real decision — and a good program can switch molecules if the first one isn't your fit. That flexibility, under genuine clinical oversight, is exactly what our Mom-Tested Score methodology rewards; clinician-led options like CoreAge Rx, my #1 pick, earn the top spot for that reason. If you're wondering whether a smaller starting dose is reasonable, see microdosing GLP-1s. Bring your history and your plans to a clinician and decide together — don't pick from a brand name. This is educational only, not medical advice, and GLP-1 medicines aren't for use in pregnancy or while trying to conceive.

Frequently asked questions

Is Zepbound better than Wegovy?

In the SURMOUNT-5 head-to-head trial, Zepbound (tirzepatide) produced more weight loss than Wegovy (semaglutide) over 72 weeks — about 20% versus 14% — and was declared superior. But that's an average across groups, not a promise for you. Tolerance, cost, insurance coverage, and contraception all matter, and a good program can switch you if the first molecule isn't right.

Does the choice matter if I'm on the pill?

Yes. The Zepbound label warns that oral contraceptives may become less effective and advises a non-oral method or an added barrier method around starting and each dose increase. The Wegovy label doesn't carry that specific warning. Tell your clinician which contraception you use before you choose.

Can I use either while breastfeeding or pregnant?

No. Both Zepbound and Wegovy are off the table during pregnancy and while breastfeeding, and both linger about a week per dose, so the washout planning is similar. If you're nursing or planning to conceive, the timing plan matters more than which molecule you pick.

References

  1. Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40353578/
  2. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  4. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. https://pubmed.ncbi.nlm.nih.gov/33755728/
  5. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. https://pubmed.ncbi.nlm.nih.gov/38078870/
  6. Johansson E, Wilding JPH, Upadhyay N, et al. (2026). Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial. Journal of Medical Economics. https://pubmed.ncbi.nlm.nih.gov/42012820/
  7. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) injection — Prescribing Information (Drug Interactions: Oral Contraceptives). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  8. U.S. Food and Drug Administration (2024). Wegovy (semaglutide) injection — Prescribing Information. DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. GLP-1 medicines aren't for use in pregnancy or while you're trying to conceive. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history.